Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNSET: QVA149 vs Triple Therapy in COPD
NCT02603393Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 4, randomised, double-blind trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Mean Change From Baseline in Post-dose Trough FEV1 at 26 weeks. Started Nov 2015; status: completed.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02603393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603393.